

### REMARKS

With the above amendment and the filing of the accompanying application data sheet Applicants now disclaim the claim to priority to:

Application No. 09/948,915 filed September 10, 2001,  
Application No. 09/425,228 filed October 22, 1999,  
Application number 09/257,266 filed February 25, 1999,  
Application number 60/115,877 and  
Application number 60/115,878 filed January 13, 1999.

This disclaimer is made in response to an obviousness type double patenting rejection in copending Application number 09/889,227. This amendment is not responsive to the issues on appeal, which are whether the specification provides an enabling disclosure for the compounds of claims 1-15 and methods of treating or preventing osteoporosis and inflammation of claim 22.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Richard J. Traverso/

---

Richard J. Traverso (Reg. No. 30,595)  
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: Bayer 0015-P04

Date: October 11, 2007